P-165 Efficacy and toxicity of FOLFIRI / aflibercept in second line colorectal cancer in real life population, retrospective study. Does first line matter?

por Fernandez Montes, A., Martinez Lago, N., Covela Rúa, M., De la Cámara Gómez, J., Méndez Méndez, J.C., Gonzalez Villarroel, P.
Publicado en Ann Oncol (2016)

Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept

por González Astorga, B., Salvà Ballabrera, F., Aranda Aguilar, E., Élez Fernández, E., García-Alfonso, P., González Flores, E., Vera García, R., Fernández Montes, A., López Muñoz, A. M., Salud Salvia, A.
Publicado en Clin Transl Oncol (2021)

Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of tra...

por Custodio, A, Carmona-Bayonas, A, Jiménez-Fonseca, P, Sánchez, M L, Viudez, A, Hernández, R, Cano, J M, Echavarria, I, Pericay, C, Mangas, M, Visa, L, Buxo, E, García, T, Rodríguez Palomo, A, Álvarez Manceñido, F, Lacalle, A, Macias, I, Azkarate, A, Ramchandani, A, Fernández Montes, A, López, C, Longo, F, Sánchez Bayona, R, Limón, M L, Díaz-Serrano, A, Hurtado, A, Madero, R, Gómez, C, Gallego, J
Publicado en Br J Cancer (2017)